RunYoung Team

RunYoung Management Team

Roger Lu

Founder and Chairman

Roger Lu has over 20 years of experience in corporate and financial management, a veteran of cross-border business with Israel and North America and has been responsible for investment in many investments over the years

He joined Sailing in 2018 as General Manager of Sailing Link Capital Management Company.

Prior to that he was with PTL where he provided investment and advisory services to the Israeli market, participated in the completion of more than 20 projects with foreign investment and the establishment of a $1 billion joint venture between Israel’s second largest fund and China Everbright Bank Fund to introduce Israeli projects to the Chinese market. He also led the completion of five projects with Chinese investment in Israeli companies; three in the healthcare sector, one in water treatment and one in the Internet sector.

Leigh Chen

Chairman and Founding Partner, TCC

Mr. Chen is the founding partner and chairman of TCC. Prior to founding TCC in 2013, Mr. Chen was an executive director at Nomura International (HK) Limited and previously a vice president at Lehman Brothers Asia Limited.

Dr. Benny Zeevi

RunYoung Israel | Partner

Dr. Benny Zeevi is a Managing General Partner at Tel Aviv Venture Partners and DFJ Tamir Fishman Ventures and leads the funds Life Science investments. He is the Founder and Co Director of an Executive Program for Biotechnology and Medical Device Entrepreneurs and Managers and serves on the advisory board of the Faculty of Management at Tel Aviv University.

Dr. Zeevi is the chairman of the boards of Vessl, Kytera and Oggii, and serves on the board of Kaiima, and Sensifree and on the advisory board of V Wave, Bionaut Lab and Data2Life. He holds a M.D. degree (Magna Cum Laude) from the Sackler School of Medicine, Tel Aviv University and has authored over 60 peer-reviewed scientific articles, in addition to various chapters in textbooks and invited reviews and editorials in pediatric cardiology journals.

Medical and Scientific Consultants

Prof. Aaron Ciechanover

Nobel Prize Winner

PhD, Israeli Biologist and Chemist.

The first Israeli to win a Nobel Prize in the sciences, Dr. Ciechanover is a member of the Israeli Academy of Humanities and Natural Sciences, a foreign member of the US National Academy of Sciences, a foreign member of the Chinese Academy of Sciences, a Distinguished University Professor at The Chinese University of Hong Kong (Shenzhen), President of the Chehanovo Institute of Precision and Regenerative Medicine and Director of the Institute of Chemical and Biomedical Sciences at Nanjing University.

Along with Dr. Avram Hershko and in collaboration with Dr. Irwin A. Rose from the Fox Chase Cancer Center in Philadelphia, Aaron discovered that covalent attachment of ubiquitin to a target protein signals it for degradation. Along the years it has become clear that ubiquitin-mediated proteolysis plays major roles in numerous cellular processes, and aberrations in the system underlie the pathogenetic mechanisms of many diseases, among them certain malignancies and neurodegenerative disorders. Consequently, the system has become an important platform for drug development.

Prof. Eli Keshet

Prof. Eli Keshet, an academician of the Israeli Academy of Sciences, received his Ph.D. in biochemistry in 1975 and then conducted postdoctoral research on retroviral integration and the reverse locus sub-subject under the direction of Nobel Laureate Howard Tymin.

From 1980 to 1981, Eli was a professor of molecular biology in the Department of Developmental Biology and Cancer Research at the Weizmann Institute, where he joined the faculty in 1982. He is a visiting scientist at the National Cancer Institute, the Curie Institute in Paris and Harvard Medical School. He is also an advisor to many major pharmaceutical companies including Roche, Schering-Plough and Novartis and recipient of numerous awards including the E.M.E.T. Prize (awarded by the Prime Minister of Israel), the Rothschild Prize, the TEVA Prize, the Bennett Prize and others.

Prof. Gad Keren

Professor Gad Keren is a professor of Cardiology at the Sackler school of Medicine and from 2002 until October 2018, he was the Head of the department of Cardiology at the Tel Aviv Sourasky Medical Center (TASMC). He is currently the director of Cardiology at the Assuta chain of Medical centers and leads the basic Cardiovascular research laboratory at TASMC. He spent years doing research at the Albert Einstein College of Medicine in New York and at the NIH in Washington DC.

Professor Keren held the Chaim Sheba Extraordinary Chair of Cardiology at the Tel Aviv University where he served as Vice dean of Curriculum of the Sackler school of Medicine. He was the president of the Israel Heart Society and served on multiple national and international Academic committees over the years, He is also the deputy editor of the IMAJ and Harefua Medical journals.

Professor Keren’s main lines of research have evolved from hemodynamics and cardiac imaging, heart failure and mechanisms of disease progression and he has authored more than 400 scientific publications and has numerous patents.

Prof. Moshe Flugelman

Prof. Moshe Flugelman specializes in interventional cardiology and vascular biology. He is the Director of the Department of Cardiovascular Medicine at the Lady Davis Carmel Medical Center, Haifa, Israel.

He was a visiting Scientist at the National Heart, Lung & Blood Institute of the National Institutes of Health (NIH) in Bethesda, Maryland and was a fellow in experimental angioplasty at Washington Hospital Center. While at the NIH, Prof. Flugelman worked with leading experts in vascular gene therapy.

Prof. Flugelman earned his Medical degree at the Technion – Israel Institute of Technology and completed his cardiology training at the Hadassah Hebrew University Medical Center in Jerusalem.

RunYoung Think Tank Industry Consultants

Prof. Ning Li

Ning Li is currently the Chief Executive Officer at Shanghai Junshi Biosciences. Before he joined Junshi Biosciences, Dr. Li had been appointed as Vice President and Head of Region Asia and China Regulatory Affairs and Medical Policy in Sanofi. He has extensive experience and expertise in clinical research and medical product evaluation.

From 1997 to 2010, Dr. Li worked at US Food and Drug Administration as a regulatory reviewer and held various positions from Oncology drug team reviewer, senior reviewer/expert reviewer, senior GCP medical reviewer to team leader, branch chief with increasing responsibilities. Dr. Li was a member of 8 technical committees and the lead or medical reviewer for more than 30 new drug applications (NDA) and over 200 investigational new drug applications (IND). Prior to his US FDA career, he worked as Sr. study director/Sr. investigator at Westat/NIH Center for Aids clinical trials, and led or participated in 9 phase I/II/III clinical studies. Before that, Dr. Li served on the faculty of Internal Medicine Department at University of Iowa and Shanghai Medical University (Fudan University).

Dr. Li obtained his medical degree from Shanghai Medical University (Fudan University) and a doctorate degree from University of Iowa. He has published more than 30 scientific papers in the area of clinical trial methodology. He is a member of Cooperative Drug Development Grants Review Committee, NIMH, NIH and Special Emphasis Panel NIDR, NIH, an adjunct faculty member at Johns Hopkins University and Peking University, a researcher at Yihong Business School of Shenyang Pharmaceutical University, and an academic advisor at the Pharmaceutical Economics Institute of Sun Yat-sen University. Dr. Li participated in the formulation of multiple FDA/NMPA clinical research technical guidelines.

Prof. Xiang Hu

Professor Hu holds the doctoral degree in biochemistry and molecular biology. He serves as the President of the Cell Research Institute affiliated to the China Medical City, the founder and CEO of Shenzhen Beike Biotechnology Co., Ltd., and the director of Beike Cell Engineering Research Institute. He has won the second prize of the National Technology Invention Awards (for the project “The Key Technology Studies and Clinical Application for Treating Refractory Autoimmune Diseases with Allosome Mesenchymal Stem Cells”). With the support of National Natural Science Foundation of China, Professor Hu has conducted a series of investigation on the pathogenesis and effective treatment of autoimmune diseases, discovered their new pathogenesis and created the new multi-mode treatment method for refractory autoimmune diseases. The allosome mesenchymal stem cell implantation treatment for refractory systematic lupus erythematosus and other autoimmune diseases is the state-of-the-art technology in this field worldwide. His research results have not only enriched the fundamental theories of the pathogenesis but also paved a new path for the treatment of refractory autoimmune diseases. It has demonstrated important scientific values and huge clinical application potentials, and have drawn great attention from his peers at home and abroad.

Jin Di Zhang

Mr. Zhang is the founder of Surgnova Healthcare Technologies. He obtained the master’s degree in biomedical engineering at Tsinghua University in 2000, and has accumulated nearly 15 years of experience as the director of technology research and development departments of GE Healthcare and Medtronic (Covidien). Before establishing his pwn start-up, Mr. Zhang was appointed as the senior director of the department of global emerging market research and development. Under his leadership, his Chinese R&D team has created numerous healthcare products which have won the trust of both doctors and patients and has mastered the core underlying algorithms.

Teng Cui

Bachelor Degree in Automotive Engineering at Shanghai Jiaotong University
MBA at Wharton Business School

Mr. Cui is the founder, chairman and CEO of Nano’s medical. Before founding Nano’s Medical, Mr. Cui Teng worked at CITIC Capital for a long time and was in charge of project investment in the medical technology industry, as well as the agriculture and biological industry in China. Before that, Mr. Cui Teng also served as a senior consultant of Boston Consulting Company, focusing on the research and projects of medical equipment and medical device industry in China. Mr. Cui Teng has extensive experience and project reserves in the investment of high-value medical equipment, implantable medical devices, advanced medical diagnostic equipment, etc.